(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 May 2018 (11.05.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/085769 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/00* (2006.01)
A61K 47/50 (2017.01) *C07K 16/28* (2006.01)
A61K 51/10 (2006.01) *C12N 15/09* (2006.01)

(21) International Application Number:
PCT/US2017/060182

(22) International Filing Date:
06 November 2017 (06.11.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/418,572 07 November 2016 (07.11.2016) US

(71) Applicant: **SEATTLE GENETICS, INC.** [US/US]; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(72) Inventors: **BHARGAVA, Swapnil**; 21823 30th Drive SE, Bothell, Washington 98021 (US). **CHEN, Cheng-Wei Aaron**; 21823 30th Drive SE, Bothell, Washington 98021 (US). **LEITH, Matthew J.**; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(74) Agent: **KIM-SZPAJDA, Jane** et al.; SEATTLE GENETICS, INC., 21823 30th Drive SE, Bothell, Washington 98021 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: DISTRIBUTION OF ENGINEERED-CYSTEINE CAPS



FIGURE 2

(57) Abstract: The present invention provides a method for removing cysteine caps from antibodies and re-capping the antibodies with cysteine molecules. The methods include, *inter alia*, culturing a host cell comprising a protein molecule having at least one capped engineered cysteine residue, and contacting the cell culture with cystine. Dissolved oxygen levels can be manipulated in the cell culture to further enhance the removal and re-capping process.

WO 2018/085769 A1

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*